Search clinical trials for: Combination of Fruquintinib and Camrelizumab

Total 147282 results

Shanghai Pulmonary Hospital, Shanghai, China

Active, not recruiting

Neoadjuvant PD-1 Antibody Plus Apatinib or Chemotherapy for Non-small Cell Lung Cancer

Non Small Cell Lung Cancer

China
Jiangsu HengRui Medicine Co., Ltd.

Active, not recruiting

A Study to Evaluate Camrelizumab Plus Rivoceranib (Apatinib) as Adjuvant Therapy in Patients With Hepatocellular Carcinoma (HCC) at High Risk of Recurrence After Curative Resection or Ablation

Hepatocellular Carcinoma (HCC)

China
Sun Yat-sen University

Recruiting

Cryoablation Combined With Camrelizumab and Apatinib in Advanced Hepatocellular Carcinoma (C-couple)

Hepatocellular Carcinoma

China
Beijing Tsinghua Chang Gung Hospital

Unknown

Study on the Effectiveness and Safety of Carrelizumab Combined With Apatinib Mesylate and Radiotherapy in the Treatment of Advanced Liver Cancer

Hepatocellular Carcinoma
NEOS Surgery
Hospital Clinic of Barcelona; Complejo Hospitalario de Navarra; Universitätsklinikum...

Recruiting

RCT to Evaluate STERN FIX Device as a Sternal Stabilization System in Patients After Sternotomy (FIXTER-2)

Median Sternotomy

Spain, Germany
Guangzhou University of Traditional Chinese Medicine

Not yet recruiting

Study of Fruquintinib Combined With Tegafur Gimeracil Oteracil in Patients With Metastatic Colorectal Cancer

Rectal Cancer | Colon Cancer | Metastasis Colorectal Cancer

China
China Medical University, China

Recruiting

A Study of Fruquintinib in Combination With Irinotecan and Capecitabine for the Second-line Treatment of Patients

Capecitabine | Fruquintinib | Gastrointestinal Tumours | Irinotecan

China
Namyi Gu

Unknown

Study of Metformin and S. Baicalensis Combination Therapy in Type 2 Diabetes Mellitus Patients

Diabetes Mellitus

Korea, Republic of
Sheba Medical Center

Active, not recruiting

MILESTONE-CD -A Prospective Multiomic Inception Real -Life Study To Evaluate Predictors of Disease Outcomes & respoNse to Biologic Treatment in Crohn's Disease (MILESTONE-CD)

Crohn Disease of Intestine

Israel
Guangxi Medical University
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

Hepatectomy Combined With Camrelizumab and Apatinib in CNLC Stage IIIb HCC

Hepatocellular Carcinoma

China
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Recruiting

Infusional FOLFOX Plus Camrelizumab and Apatinib vs HAIC-FOLFOX Plus Camrelizumab and Apatinib for Advanced HCC

Chemotherapy Effect | BCLC Stage C Hepatocellular Carcinoma

China
Sun Yat-sen University
Wuzhou Red Cross Hospital; Fifth Affiliated Hospital, Sun Yat-Sen University; Affiliated Cancer Hospital & Institute of Guangzhou Medical University and other collaborators

Recruiting

Concurrent and Adjuvant PD1 Treatment Combined With Chemo-radiotherapy for High-risk Nasopharyngeal Carcinoma

Nasopharyngeal Cancer | Chemotherapy | Radiotherapy | PD-1 Therapy

China
Sichuan University

Not yet recruiting

The Effectiveness and Safety of Camrelizumab/Lenvatinib Combined With TACE in Patients With Borderline Resectable HCC

Carrelizumab Plus Lenvatinib Combined With TACE | Borderline Resectable Hepatocellular Carcinoma

China
Henan Cancer Hospital

Recruiting

Camrelizumab Combined With Apatinib for Advanced Gastric or Esophagogastric Adenocarcinoma

Advanced Gastric Carcinoma

China
Zhejiang Cancer Hospital

Recruiting

The Combination of Camrelizumab and Apatinib as Second-line Therapy for Advanced Pancreatic Carcinoma

Pancreatic Cancer

China
Jiangsu HengRui Medicine Co., Ltd.

Terminated

A Study to Evaluate Camrelizumab Combined With Famitinib as Subsequent Therapy in Patients With Advanced NSCLC

Advanced NSCLC

China
The First Affiliated Hospital of Soochow University
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

PD-1 Inhibitor, Azacitidine and Low-dose DLI in AML Relapse After Allo-HSCT

Acute Myeloid Leukemia

China
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Recruiting

mFOLFOX7 Plus Camrelizumab and Apatinib for Advanced HCC

Stage III Hepatocellular Cancer (CNLC Staging)

China
Hunan Cancer Hospital
Jiangsu Hengrui Pharmaceuticals Co.,Ltd

Recruiting

A Study of Camrelizumab Combined Apatinib in Hepatocellular Carcinoma Previously Treated With Immune Checkpoint Inhibitors (ICIs).

Hepatocellular Carcinoma | Immune Checkpoint Inhibitors

China
Peking University First Hospital

Not yet recruiting

Observational Study of Camrelizumab Combined With Apatinib and Hyperfractionated Radiotherapy for Renal Cell Carcinoma

Renal Cell Carcinoma
Zhejiang University
Huashan Hospital; West China Hospital; The First Affiliated Hospital of Zhengzhou... and other collaborators

Unknown

Combination Camrelizumab (SHR-1210) and Apatinib for Downstaging/Bridging of HCC Before Liver Transplant

Hepatocellular Carcinoma | Liver Transplant

China
Henan Cancer Hospital

Recruiting

Camrelizumab Combined With Apatinib Mesylate

Solid Tumor

China
Sun Yat-sen University

Completed

SHR-1210 in Combination With Apatinib in Patients With Metastatic, Persistent, or Recurrent Cervical Cancer

Recurrent Cervical Carcinoma | Metastatic Cervical Cancer

China
Raymond T. Chung, MD
Merck Sharp & Dohme LLC

Withdrawn

Preemptive Zepatier Treatment in Donor HCV Positive to Recipient HCV Negative Cardiac Transplant

Hepatitis C | Cardiac Transplant Disorder

United States
Shandong Cancer Hospital and Institute
Jiangsu HengRui Medicine Co., Ltd.

Active, not recruiting

A Trial of Conversion Treatment of HAIC Combined With Camrelizumab and Apatinib for Unresected Hepatocellular Carcinoma

Hepatocellular Carcinoma

China
PharmaKing

Completed

Comparative Evaluate the Efficacy to Acute and Chronic Bronchitis

Acute Exacerbation of Chronic Bronchitis

Korea, Republic of
Nanfang Hospital of Southern Medical University

Recruiting

Hepatic Arterial Infusion Combined With Lenvatinib and Camrelizumab for Unresectable Hepatocellular Carcinoma

Hepatocellular Carcinoma

China
Shanghai Zhongshan Hospital

Not yet recruiting

Camrelizumab in Patients With Unresectable Hepatocellular Carcinoma

Unresectable Hepatocellular Carcinoma
The First Affiliated Hospital of Xiamen University

Not yet recruiting

Camrelizumab Combined With Apatinib Mesylate and Standard Chemotherapy (Pemetrixed + Carboplatin) in Patients With Tyrosine Kinase Inhibitor Failure in ALK-positive Advanced NSCLC

Lung Neoplasms
Alzheimer's Light LLC

Recruiting

Alzheimer's Disease Treatment With Combination of 40Hz Light and Cognitive Therapy (AlzLife)

Dementia | Alzheimer Disease | Mild Cognitive Impairment | Cognitive Decline | Cognitive Deterioration | Cognition Disorders in Old Age

United States
Yonsei University

Recruiting

Combination Therapy of Atherectomy Plus Drug-coated Balloon Versus Drug-coated Balloon for Complex Femoropopliteal Artery Disease (ARTEMIS)

Femoropopliteal Artery Disease

Korea, Republic of
The Cleveland Clinic

Recruiting

Virtual and Video Counseling Versus In-Office Counseling for Laparoscopic Hysterectomy

Patient Engagement

United States
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Not yet recruiting

A Clinical Study of a Preoperative Translational Therapy for Unresectable Gallbladder Cancer

Unresectable Gallbladder Cancer

China
Fujian Medical University

Not yet recruiting

Clinical Efficacy in Neoadjuvant Treatment of Locally Advanced Gastric Cancer With Different Immunotypes

Locally Advanced Gastric Cancer

China
Shanghai Proton and Heavy Ion Center

Recruiting

Carbon-Ion Radiotherapy Plus Camrelizumab for Locally Recurrent Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma

China
Qilu Pharmaceutical Co., Ltd.

Active, not recruiting

A Phase II/III Trial to Evaluate the Efficacy and Safety of QL1706 in Patients With Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma

China
UNICANCER
Novartis

Completed

Phase I Evaluating the Combination of Ribociclib+Capecitabine in Locally Advanced/Metastatic Breast Cancer HER2 Negative (GEP14-LEECAP)

Breast Cancer

France
Zhejiang Cancer Hospital

Not yet recruiting

HIPEC Combined With Camrelizumab, Paclitaxel and S-1 for Conversion Therapy in Patients With Advanced Gastric Cancer With Peritoneal Metastasis

Gastric Cancer, HIPEC, Anti-PD-1 Antibody Camrelizumab (SHR-1210), Chemotherapy and Surgery

China
Fudan University

Not yet recruiting

Camrelizumab and Apatinib for Neoadjuvant Therapy in Thyroid Cancer

Thyroid Cancer

China
Université de Lubumbashi
Centers for Disease Control and Prevention; Universiteit Antwerpen

Unknown

Effectiveness Study of New Generation Bednets in the Context of Conventional Insecticide Resistance in the Democratic Republic of the Congo (Net-PBO)

Insecticide Resistance

Congo, The Democratic Republic of the
The First Affiliated Hospital with Nanjing Medical...

Recruiting

Fruquintinib Combined With Sintilimab and Chemotherapy in the Treatment of Non-Small Cell Lung Cancer

Carcinoma, Non-Small-Cell Lung

China
Hutchison Medipharma Limited

Completed

A Phase Ib/2 Clinical Study of Fruquintinib Combined With Paclitaxel in the Treatment of Advanced Gastric Cancer

Gastric Cancer

China
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

Study of Camrelizumab (SHR-1210) vs. Chemotherapy in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma

Classical Hodgkin Lymphoma

China
HRYZ Biotech Co.

Recruiting

MASCT-I Combined With Apatinib and/or Camrelizumab in the Treatment of Bone and Soft Tissue Sarcoma

Sarcoma

China
Fudan University

Not yet recruiting

A Clinical Study of the Efficacy and Safety of Chidamide in Combination With Camrelizumab and Carboplatin or Capecitabine in the Second and Third Line Treatment of Relapsed/Metastatic Triple-negative Breast Cancer

Triple-negative Breast Cancer

China
Cancer Institute and Hospital, Chinese Academy...

Not yet recruiting

A Neoadjuvant Hepatocellular Carcinoma Study of Camrelizumab in Combination With Apatinib and Oxaliplatin

Hepatocellular Carcinoma Resectable
Peking Union Medical College Hospital

Unknown

Camrelizumab /Apatinib for Recurrent Platinum-resistant Ovarian Cancer

Recurrent Platinum-resistant Ovarian Cancer

China
Deutsches Herzzentrum Muenchen

Completed

Comparison of Strategies for Vascular Access Closure After Transcatheter Aortic Valve Implantation (ACCESS-TAVI)

Aortic Valve Stenosis

Germany
Beijing Friendship Hospital

Unknown

Efficacy and Safety of Camrelizumab for Injection, Apatinib Mesylate and Tegio for First-line Refractory Patients With Advanced Gastric Cancer

Gastric Cancer

China
University of Wisconsin, Madison
National Cancer Institute (NCI)

Enrolling by invitation

Cessation Screening Project

Nicotine Dependence

United States

3

Subscribe